Literature DB >> 26742526

Acute Morphine, Chronic Morphine, and Morphine Withdrawal Differently Affect Pleiotrophin, Midkine, and Receptor Protein Tyrosine Phosphatase β/ζ Regulation in the Ventral Tegmental Area.

Daniel García-Pérez1,2, M Luisa Laorden3,4, M Victoria Milanés3,4.   

Abstract

Pleiotrophin (PTN) and midkine (MK) are secreted growth factors and cytokines, proposed to be significant neuromodulators with multiple neuronal functions. PTN and MK are generally related with cell proliferation, growth, and differentiation by acting through different receptors. PTN or MK, signaling through receptor protein tyrosine phosphatase β/ζ (RPTPβ/ζ), lead to the activation of extracellular signal-regulated kinases (ERKs) and thymoma viral proto-oncogene (Akt), which induce morphological changes and modulate addictive behaviors. Besides, there is increasing evidence that during the development of drug addiction, astrocytes contribute to the synaptic plasticity by synthesizing and releasing substances such as cytokines. In the present work, we studied the effect of acute morphine, chronic morphine, and morphine withdrawal on PTN, MK, and RPTPβ/ζ expression and on their signaling pathways in the ventral tegmental area (VTA). Present results indicated that PTN, MK, and RPTPβ/ζ levels increased after acute morphine injection, returned to basal levels during chronic opioid treatment, and were upregulated again during morphine withdrawal. We also observed an activation of astrocytes after acute morphine injection and during opiate dependence and withdrawal. In addition, immunofluorescence analysis revealed that PTN, but not MK, was overexpressed in astrocytes and that dopaminergic neurons expressed RPTPβ/ζ. Interestingly, p-ERK 1/2 levels during chronic morphine and morphine withdrawal correlated RPTPβ/ζ expression. All these observations suggest that the neuroprotective and behavioral adaptations that occur during opiate addiction could be, at least partly, mediated by these cytokines.

Entities:  

Keywords:  Glial fibrillary acidic protein; Midkine; Opiate dependence; Pleiotrophin; Reward pathway

Mesh:

Substances:

Year:  2016        PMID: 26742526     DOI: 10.1007/s12035-015-9631-2

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  65 in total

Review 1.  Reactive astrocytes: cellular and molecular cues to biological function.

Authors:  J L Ridet; S K Malhotra; A Privat; F H Gage
Journal:  Trends Neurosci       Date:  1997-12       Impact factor: 13.837

2.  Genetic inactivation of pleiotrophin triggers amphetamine-induced cell loss in the substantia nigra and enhances amphetamine neurotoxicity in the striatum.

Authors:  E Gramage; L Rossi; N Granado; R Moratalla; G Herradón
Journal:  Neuroscience       Date:  2010-07-08       Impact factor: 3.590

Review 3.  Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Authors:  G Herradón; C Pérez-García
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

4.  Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease.

Authors:  Rui D S Prediger; Argelia E Rojas-Mayorquin; Aderbal S Aguiar; Caroline Chevarin; Raymond Mongeau; Michel Hamon; Laurence Lanfumey; Elaine Del Bel; Hisako Muramatsu; José Courty; Rita Raisman-Vozari
Journal:  J Neural Transm (Vienna)       Date:  2011-02-08       Impact factor: 3.575

Review 5.  Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex.

Authors:  Satoshi Ikemoto
Journal:  Brain Res Rev       Date:  2007-05-17

6.  Midkine, heparin-binding growth factor, blocks kainic acid-induced seizure and neuronal cell death in mouse hippocampus.

Authors:  Yun B Kim; Jae K Ryu; Hong J Lee; In J Lim; Dongsun Park; Min C Lee; Seung U Kim
Journal:  BMC Neurosci       Date:  2010-03-26       Impact factor: 3.288

7.  Glial fibrillary acidic protein and the mesolimbic dopamine system: regulation by chronic morphine and Lewis-Fischer strain differences in the rat ventral tegmental area.

Authors:  D Beitner-Johnson; X Guitart; E J Nestler
Journal:  J Neurochem       Date:  1993-11       Impact factor: 5.372

8.  Morphine administration modulates expression of Argonaute 2 and dopamine-related transcription factors involved in midbrain dopaminergic neurons function.

Authors:  D García-Pérez; F Sáez-Belmonte; M L Laorden; C Núñez; M V Milanés
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

9.  delta-9-Tetrahydrocannabinol regulates gene expression of the growth factor pleiotrophin in the forebrain.

Authors:  P Mailleux; X Preud'homme; N Albala; J M Vanderwinden; J J Vanderhaeghen
Journal:  Neurosci Lett       Date:  1994-07-04       Impact factor: 3.046

10.  Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells.

Authors:  Cha-Gyun Jung; Hideki Hida; Kensuke Nakahira; Kazuhiro Ikenaka; Hye-Jung Kim; Hitoo Nishino
Journal:  FASEB J       Date:  2004-06-04       Impact factor: 5.191

View more
  3 in total

1.  Dorsal hippocampal interleukin-1 signaling mediates heroin withdrawal-enhanced fear learning.

Authors:  Shveta V Parekh; Jacqueline E Paniccia; Christina L Lebonville; Donald T Lysle
Journal:  Psychopharmacology (Berl)       Date:  2020-08-28       Impact factor: 4.530

Review 2.  The Role of Cell Adhesion Molecule Genes Regulating Neuroplasticity in Addiction.

Authors:  Dawn E Muskiewicz; George R Uhl; F Scott Hall
Journal:  Neural Plast       Date:  2018-02-20       Impact factor: 3.599

3.  Prefrontal Cortex Response to Prenatal Insult and Postnatal Opioid Exposure.

Authors:  Haley E Rymut; Laurie A Rund; Bruce R Southey; Rodney W Johnson; Jonathan V Sweedler; Sandra L Rodriguez-Zas
Journal:  Genes (Basel)       Date:  2022-07-30       Impact factor: 4.141

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.